Tuesday, January 17, 2017 3:16:46 PM
* Massive insider buying, Ceo now owns 26% of the company and has added another 12.5 million shares in the last 6 months!
* 0 short or long term debt
* Phase 1/2 human clinical trials starting soon.
----------------------------------------------------------------
PROTOKINETIX INC. (OTCMKTS:PKTX) IS ATTRACTING SMART MONEY
written by Jack Delahunty January 5, 2017
The biotech sector struggled throughout the latter half of 2016, as markets priced in expectations of a Democratic term in the White House, and what this might mean for drug pricing. Forced lower pricing would reduce big name investment, and this could hurt the smaller companies’ potential to expand into the commercialization phase. With Trump set to take the helm, this fear is allayed (at least for now) and this transaction illustrates this fact.
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Protokinetix Inc. (OTCMKTS:PKTX) reported that Young Lachlan Grant has picked up 22,850,000 of common stock as of 2017-01-05.
The acquisition brings the aggregate amount owned by Young Lachlan Grant to a total of 22,850,000 representing a 9.0% stake in the company.
For those not familiar with the company, ProtoKinetix, Incorporated is a research and development-stage bio-technology company. The Company is focused on scientific medical research of Anti-Freeze Glycoproteins (AFGPs) or anti-aging glycoproteins, known as AAGPs. AFGP is found in nature as a compound produced by some fish, insects, reptiles, bacteria and plants that enable survival in freezing temperatures. Health Care Applications of AAGP fall into various categories, such as harvesting, storage and transplanting cells, tissues and organs, and treatments for conditions and diseases caused by stress factors, including ultraviolet (UV) radiation, oxidation and inflammation. The Company is engaged in preparing to start Phase I and Phase II human clinical trials at the University of Alberta.
A glance at Protokinetix Inc. (OTCMKTS:PKTX)’s key stats reveals a current market capitalization of 12.37 million based on 227.45 million shares outstanding and a price at last close of $0.054 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-20, Smith picked up 4,000,000 at a purchase price of $0.04. This brings their total holding to 53,070,500 as of the date of the filing.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Protokinetix Inc. (OTCMKTS:PKTX) as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.
Recent SBFM News
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:05:31 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 03/05/2024 09:37:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 09:05:35 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/23/2024 09:03:01 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/21/2024 09:28:39 PM
- Form PRE 14C - Other preliminary information statements • Edgar (US Regulatory) • 02/21/2024 01:24:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 10:01:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 04:39:32 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 08:53:03 PM
- Form 424B4 - Prospectus [Rule 424(b)(4)] • Edgar (US Regulatory) • 02/14/2024 04:18:31 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 02/13/2024 05:15:10 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 09:05:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 02:04:50 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 02/09/2024 10:17:56 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/01/2024 09:17:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 05:38:24 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/08/2024 01:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/07/2023 09:59:51 PM
- Sunshine Biopharma Moves Principal Office to New York City • GlobeNewswire Inc. • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 01:00:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 04:18:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/20/2023 05:06:33 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/19/2023 04:10:36 PM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM